Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics by unknown
RESEARCH ARTICLE Open Access
Yersinia pseudotuberculosis infection
in Kawasaki disease and its clinical
characteristics
Tomoko Horinouchi1, Kandai Nozu2*, Kiyoshi Hamahira1, Yosuke Inaguma1, Jun Abe3, Hiroshi Nakajima4,
Masaaki Kugo1 and Kazumoto Iijima2
Abstract
Background: The etiology of Kawasaki disease (KD) is unknown. Reportedly, there is an association between KD
and Yersinia pseudotuberculosis (YPT). Steroid therapy for KD patients with high risk of cardiac sequelae (CS) has
been reported; however, the number of reports is limited.
Methods: We conducted a prospective study of 108 patients with newly diagnosed KD in one year to determine
how many KD patients have positive anti-YPT antibody titers and/or positive anti-YPT-derived mitogen (YPM)
antibody titers. In addition, we tried to identify clinical differences between KD patients in whom YPT infection was
or not a contributing factor. We also compared clinical characteristics of patients treated with the protocol of the
Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease (RAISE) study
(RAISE group) and with the conventional Intravenous immunoglobulin (IVIG) protocol (conventional group).
Results: Eleven patients (10 %) were positive for anti-YPT and/or anti-YPM antibodies (positive group) and 97
(90 %) were negative (negative group). Cardiac sequelae (CS) occurred significantly more frequently in the positive
than the negative group (two patients, 18 % vs one patient, 1 %, p = 0.027). Forty patients were in the RAISE group.
Two of 40 (5 %) in the RAISE group and one of 68 (1.47 %) in the conventional group had CS (p = 0.55).
Conclusions: KD patients with YPT infection had CS significantly more frequently and treatment with RAISE
protocol did not decrease the frequency of CS in our cohort, nor did YPT infection affect risk scores of no response
to IVIG. However, our sample size was overly small to draw such conclusions. Further investigation in a larger
cohort is necessary to confirm our findings. Additionally, further research is needed to determine whether early
diagnosis of YPT can prevent KD from developing and reduce the incidence of CS.
Background
Kawasaki disease (KD), a febrile vasculitis of unknown
origin, can cause coronary artery dilation and is increas-
ing in incidence worldwide [1–3]. Identification of the
cause and optimal treatment is urgently needed.
Yersinia pseudotuberculosis (YPT), an enteric patho-
gen, causes a variety of clinical symptoms such as fever,
rash, desquamation, strawberry tongue, lymphadenop-
athy, and conjunctivitis that sometimes satisfy the clinical
criteria for KD. Some research groups have reported an
association between YPT and KD [4–7]. YPT is commonly
typed serologically according to antigenic differences
in the lipopolysaccharide O antigen. There are 15 ser-
ogroups; serotypes O:1 and O:2 have subtypes a, b, and c,
and serotypes O:4 and O:5 have subtypes a and b. Thus,
there are 21 serotypes in all [8, 9]. Serotypes O:1a, O:1b,
O:2a, O:2b, O:2c, O:3, O:4b, O:5a, O:5b, O:6, O:10, and
O:15 are known to be pathogenic for humans [10]. The
pathogenicity of YPT is determined by a number of viru-
lence factors, including a plasmid associated with Yersinia
virulence, a high-pathogenicity island, and a Y. pseudotu-
berculosis-derived mitogen (YPM) [11–13]. Among these
virulence factors, YPM is a superantigen that activates
macrophages and T cells and causes symptoms such as
high fever and erythema [14].* Correspondence: nozu@med.kobe-u.ac.jp2Department of Pediatrics, Kobe University Hospital, Kobe, Japan
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So far, few reports concerning the relationship between
KD and YPT infection are available. The present study
was designed to determine how often KD patients have as-
sociated YPT infection by assessing anti-YPT and anti-
YPM antibody titers and to identify clinical differences
between KD patients with and without YPT infection.
Additionally, about 40 % of KD patients in our cohort
were treated with the RAISE (Randomized controlled
trial to Assess Immunoglobulin plus Steroid Efficacy for
Kawasaki disease) study protocol [15]. Clinical character-
istics of patients treated with the RAISE protocol and
the conventional IVIG (IntraVenous ImmunoGlobulin)
protocol were compared to assess the effects of the
RAISE study treatment strategy in patients with KD and
the influence of YPT infection on treatment outcomes.
Methods
Study patient definitions and design
With approval of the Japanese Red Cross Society Himeji
Hospital ethics committee, all KD patients hospitalized
from April 2013 to March 2014 in the Japanese Red
Cross Society Himeji Hospital were prospectively in-
cluded in this study. Written informed consent for not
only participating in this study but also to publish the
patient data and information was obtained from all
parents or guardians. Patients whose guardians refused
consent or for whom blood samples for detection of
anti-YPT and YPM antibodies were not available were
excluded. Acute- and convalescent-phase sera were ob-
tained from participants, who were then divided into
two groups: a positive group (positive anti-YPT and/or
positive anti-YPM antibody titers) and a negative group
(both anti-YPT and anti-YPM antibody titers negative).
The following clinical data were recorded and com-
pared between the two groups: sex, age, duration of
fever in days, frequency of administration of high-dose
IVIG, acute-phase coronary artery dilation, cardiac se-
quelae (CS), abdominal symptoms, white blood cell and
absolute neutrophil counts, serum concentrations of albu-
min, total bilirubin, aspartate aminotransferase, sodium,
C-reactive protein (CRP), procalcitonin, N-terminal pro-
brain natriuretic peptide, and soluble interleukin-2 recep-
tor, and urinary β2-microglobulin/creatinine ratio.
Measurement of anti-YPT antibody and anti-YPM antibody
To identify and quantitate anti-YPT antibodies, lipopoly-
saccharide agglutination titers for serotypes O:1a, 1b, 2a,
2b, 3, 4a, 4b, 5a, 5b, and 6 were measured by the Widal
method. Sera positive for O:2 and/or O:4 were retested
after absorption with Salmonella O groups four and
nine, respectively, because the former have cross-O-
antigen reaction against the latter [16, 17]. The cut-off
for positive anti-YPT antibodies was a single titer of
1:160 or higher [10].
Enzyme-linked immunosorbent assays were performed
to measure anti-YPM antibodies, the optical density of
non-antigen-coated wells being subtracted from that of
antigen-coated wells. Anti-YPM antibody titers were de-
termined using a calibration curve constructed from a
positive control serum. Patients with a more than four-
fold increase in serial antibody titers were considered
positive for anti-YPM antibodies.
Definition and treatments for KD
Kawasaki disease was diagnosed in accordance with the
Japanese Diagnostic Guidelines for Kawasaki Disease
(5th edition) [17]. The initial treatment for KD consisted
of IVIG (2 g/kg) (n = 108). A second dose of IVIG (2 g/
kg) was given to patients whose fever had not resolved
≥48 h after receiving the first IVIG (n = 27). For patients
whose fever had not resolved ≥48 h after receiving a sec-
ond IVIG, additional treatments, including a third ad-
ministration of IVIG (2 g/kg) (n = 12), infliximab (5 mg/
kg) (n = 5), cyclosporin (4 mg/kg per day, until CRP con-
centrations had reverted to normal) (n = 2), or methyl-
prednisolone (30 mg/kg per day, for 3 days) (n = 2) were
considered. No patient underwent plasma exchange
(Fig. 1). Almost all patients received aspirin 30 mg/kg
per day until they were afebrile, followed by aspirin
3 mg/kg per day for 2 months after discharge from the
hospital. Flurbiprofen (4 mg/kg/day) was substituted in
patients with serum aspartate aminotransferase or ala-
nine aminotransferase concentrations ≥200 U/L.
Coronary artery dilation was defined as the internal
diameter of the coronary artery being >3 mm (>4 mm if
the subject was over 5 years old) or the internal diameter
of a segment being at least 1.5 times that of an adjacent
segment according to echocardiography [18]. Acute-
phase coronary artery dilations were defined as those
that normalized within 1 month and CS were defined as
those remaining after 1 month [15].
RAISE study group
The treatment strategy was changed during the study
period. At first, we started the KD treatment with the
conventional IVIG protocol. However, we decided to
change the treatment protocol, that is, we adopted the
RAISE protocol, which reported clear evidence that ste-
roids prevent CS in KD patients [15] and has already
been adopted as a standard treatment in Japan which re-
flects the fact that this protocol has recently described in
the guideline for treatment of KD in Japan [18, 19].
In response to the findings of the RAISE study, be-
tween December 2013 and March 2014, patients with
risk scores ≥5 points, which predicts failure to respond
to initial treatment with IVIG, we adopted the RAISE
protocol which reported clear evidence that intravenous
prednisolone (PSL) 2 mg/kg per day (maximum dose of
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60 mg per day) prevents CS in KD [15]. Once patients
had become afebrile, PSL was administered orally. When
serum CRP concentrations had decreased to within the
normal range (≤0.5 mg/dL), the PSL dose was tapered
over 15 days with the following dosage reductions at
5 day intervals: from 2 mg/kg per day to 1 mg/kg per
day to 0.5 mg/kg per day. Scoring and cut-off values for
risk scores were measured as described in the RAISE
study, which is as follows: two points each for serum so-
dium concentration of ≤133 mmol/L, ≤4 days of illness
at diagnosis, serum aspartate aminotransferase concen-
tration of ≥100 U/L, neutrophil count of ≥80 %; and 1
point each for platelet count ≤30 × 104/μL, serum CRP
concentration of ≥10 mg/dL, and age ≤12 months [15].
Patients with risk scores of ≥5 points were regarded as
high risk. Patients who were treated according to the
RAISE study protocol were defined as the RAISE group
and the others were defined as the conventional group.
Statistical analysis
The Mann–Whitney U test was performed to compare
continuous variables between these two groups and
Fisher’s exact test for categorical variables. Differences
were considered significant if p < 0.05. Data are expressed
as median and interquartile range. All calculations were
performed with standard statistical software (JMP version
11 package for Windows, SAS, Cary, NC, USA).
Results
During the year of the study, 113 patients with KD were
admitted to our hospital. After excluding five patients,
one because their guardian refused consent and four for
whom blood samples were not available, 108 patients
were included in the study (Fig. 1).
Eleven patients (10 %) were in the positive group, and
97 (90 %) in the negative group. Of the eleven patients
in the positive group, eight were positive only for anti-
YPT antibodies, one for only anti-YPM antibody and two
for both (Table 1). Patients 7 (O:2b, 5b), 9 (O:5a, 5b), and
11 (O:1b, 2b) had increases in titers of more than two
types of antibody.
Clinical manifestations of patients with KD according
to serologically positive and negative groups are com-
pared in Table 2. The only significant differences be-
tween the two groups were in the incidence of CS
(positive group, two patients [18 %] vs negative group,
Fig. 1 Flow chart showing distribution of study subjects and medications used for KD. The numbers in parentheses denote the overall number of
patients. KD: Kawasaki disease, IVIG: IntraVenous ImmunoGlobulin, IFX: Infliximab, CyA: cyclosporin, mPSL: methylprednisolone
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one patient [1 %]; p = 0.027) and of abdominal symptoms
(positive group, eight patients [73 %] vs negative group,
33 patients [34 %]; p = 0.020).
Although blood and/or stool cultures were performed
in many patients in this study, YPT was not cultured
from any of the samples.
Figures 2 and 3 show the medications and the number
of patients overall, whose risk scores were ≥5 points, in
the conventional group and the RAISE group, respect-
ively. Forty of 108 patients were treated according to the
RAISE study protocol [15] (RAISE group). Ten patients
in the RAISE group had positive risk scores and received
IVIG + PSL therapy (Fig. 3). As shown in Table 3, there
were no significant differences in clinical characteristics
between patients in the RAISE and conventional groups.
Two of 40 patients (5 %) in the RAISE group and one of
68 (1.47 %) in the conventional group had CS (p = 0.55).
Further, two of 10 patients (20 %) with positive risk
scores in the RAISE group (one YPT positive and one
YPT negative) and one of 19 patients (5.26 %) with posi-
tive risk scores in the conventional group (YPT positive)
had CS (p = 0.27).
Table 1 Characteristics of patients in positive group
No Age (months) Sex YPT YPM CS Treatment group Risk group
1 19 Male O6 (1:640) Negative (−) Conventional Low
2 29 Female O6 (1:160) Negative (−) Conventional Low
3 72 Male O3 (1:640) Negative (−) Conventional Low
4 6 Male Negative Positive (−) Conventional Low
5 66 Male O5b (1:160) Negative (+) Conventional High
6 34 Female O6 (1:160) Negative (−) RAISE Low
7 22 Male O2b,5b (1:160) Negative (+) RAISE High
8 70 Male O1a (1:160) Negative (−) RAISE Low
9 21 Female O5a,5b (1:160) Positive (−) RAISE Low
10 79 Female O6 (1:160) Negative (−) RAISE High
11 21 Female O1b,2b (1:160) Positive (−) RAISE Low
Table 2 Comparison of characteristics according to serologically positive and negative groups
Positive group (n = 11) Negative group (n = 97) P value
Sex (male/female) 6/5 61/36 0.74
Age (months) 29 (21–70) 24 (13–49.5) 0.26
Duration of fever (days) 6 (6–9) 5 (5–7) 0.092
Frequency of administration of IVIG 1 (1–2) 1 (1–1) 0.32
Acute-phase coronary artery dilation; n (%) 2 (18.18 %) 4 (4.12 %) 0.11
CS; n (%) 2 (18.18 %) 1 (1.03 %) 0.027
Abdominal symptoms; n (%) 8 (72.73 %) 33 (34.02 %) 0.02
White blood cell count (/μ L) 12,900 (11,100–19,400) 13,000 (10,750–15,400) 0.48
Absolute neutrophil count (/μ L) 8117 (5741–24,654) 8032 (5696–10,240) 0.73
Serum albumin concentration (g/dL) 3.8 (3.4–4) 3.7 (3.4–4) 0.54
Serum total bilirubin concentration (mg/dL) 0.4 (0.3–0.7) 0.6 (0.4–0.8) 0.47
Serum aspartate aminotransferase (U/L) 37 (19–230) 32.5 (25–69.25) 0.8
Serum sodium (mmol/L) 134 (133–138) 136 (134–138) 0.24
Serum CRP concentration (mg/dL) 4.36 (1.81–8.09) 7.09 (3.09–11.72) 0.27
Serum procalcitonin concentration (ng/mL) 0.67 (0.42–2.18) 0.47 (0.175–1.995) 0.37
N-terminal pro-brain natriuretic peptide (pg/mL) 379 (81.75–771.5) 386 (140–936) 0.74
Serum soluble interleukin-2 receptor (U/mL) 1560 (1350–2680) 1635 (1062.5–2157.5) 0.37
Urinary β 2-microglobulin/creatinine ratio 101.9 (10.7–203.7) 18.9 (5.9–126.3) 0.25
High risk patients; n (%) 3 (27.27 %) 26 (27.08 %) 1
Values expressed as count (%) for categorical variables and median (IQR) for continuous variables
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These findings indicate that the RAISE study treat-
ment protocol (IVIG + PSL for high-risk patients with
no response to IVIG and IVIG for low-risk patients) did
not decrease the frequency of CS in our cohort. Add-
itionally, YPT infection did not affect risk scores of no
response to IVIG in either RAISE or the conventional
period.
Discussion
This is the first study to comprehensively investigate
KD patients for evidence of YPT infection by asses-
sing both anti-YPT antibodies for serotypes that can
infect humans and YPM antibodies. We also analyzed
the effect of the RAISE regimen to prevent CS devel-
opment in KD.
Fig. 2 Flow chart showing the distribution of study subjects and medications used for KD in the conventional group. The numbers in parentheses
denote the overall number of patients in the conventional group, and the number of patients in the conventional group whose risk scores were ≥5
points, respectively. IVIG: intravenous immunoglobulin, IFX: infliximab, CyA: cyclosporin, mPSL: methylprednisolone
Fig. 3 Flow chart showing the distribution of study subjects and medications used for KD in the RAISE group. The numbers in parentheses
denote the overall number of patients in the RAISE group, and the number in the RAISE group who received PSL because of risk scores ≥5
points, respectively. IVIG: intravenous immunoglobulin, IFX: infliximab, CyA: cyclosporin, mPSL: methylprednisolone
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This study yielded four important clinical observa-
tions. First, 11/108 KD patients (10 %) had positive titers
of anti-YPT and/or anti-YPM antibodies. Second, the in-
cidence of CS was significantly higher in the serologic-
ally positive (two patients, 18 %) than in the negative
group (one patient, 1 %) (p = 0.027). Third, there were
no clinical differences between the serologically positive
and negative groups, except for the incidence of abdom-
inal symptoms and CS. Fourth, in our cohort, the use of
the RAISE study protocol, comprising IVIG + PSL ther-
apy, did not decrease the frequency of CS in high-risk
patients, neither did YPT infection influence sensitivity
to treatment.
In 1983, Sato et al. reported that 2/12 patients with
YPT fulfilled the criteria for KD [20]. Since then, several
other groups have confirmed an association between
YPT infection and KD. Baba et al. reported that, from
1981 to 1989, 29/329 of their YPT patients fulfilled the
criteria for KD [5]. In 2006, Tahara et al. reported that,
from 1985 to 2004, 42/452 of their KD patients had bac-
teriological culture and/or serological evidence of YPT
infection [7]. Although the percentage of KD patients
with YPT infection in our study is similar to that in
previous reports, the ratio may differ in other regions
because geographical heterogeneity of YPT strains has
been reported [21, 22].
We found increases in more than two types of anti-
bodies in three patients (Patients 7, 9 and 11; Table 1).
These findings may reflect-specific responses; however,
two of these three patients were also positive for anti-
YPM antibodies (Patients 9 and 11), which makes non-
specific reactions unlikely. A search of published reports
revealed no reports of cross-reacting antigens between
different strains of YPT or of co-infection with more
than two types of YPT in humans. Fukushima et al. de-
scribed a patient infected with O serotype-untypeable
strains with positive titers for two serological types of
YPT [11]. Additionally, discrepancies between classical
serotypes and O-genotypes have been reported [8]. Thus,
there may be some new or untypeable strains of YPT.
Three of 11 patients in the serologically positive group
(27 %) were positive for anti-YPM antibodies and two of
three for both anti-YPT and anti-YPM antibodies. In
1993, Abe et al. demonstrated that YPT produce a
superantigen, YPM [23, 24]. In 1995, Yoshino et al. re-
ported that 95 % of YPT strains in Japan harbor the ypm
Table 3 Characteristics of patients according to study group
RAISE group (n = 40) Conventional group (n = 68) P value
Sex (male/female) 23/17 44/24 0.54
Age (months) 29 (16.25–47.75) 23 (13–51.75) 0.44
Duration of fever (days) 5.5 (5–6.75) 6 (5–8) 0.21
Frequency of administration of IVIG 1 (1–1) 1 (1–2) 0.11
Acute-phase coronary artery dilation; n (%) 3 (7.5 %) 3 (4.41 %) 0.67
CS; n (%) 2 (5 %) 1 (1.47 %) 0.55
Abdominal symptoms; n (%) 18 (45 %) 23 (33.82 %) 0.31
White blood cell count (/μ L) 13,250 (11,700–17,200) 12,700 (10,200–15 100) 0.057
Absolute neutrophil count (/μ L) 8547 (7195–11,520) 7482 (5356–10,086) 0.057
Serum albumin concentration (g/dL) 3.7 (3.4–3.9) 3.7 (3.3–4) 0.53
Serum total bilirubin concentration (mg/dL) 0.6 (0.4–0.775) 0.6 (0.4–0.8) 1
Serum aspartate aminotransferase (U/L) 37 (28–80.75) 29 (22–71) 0.079
Serum sodium concentration (mmol/L) 136 (134–138) 136 (134–137) 0.12
Serum CRP concentration (mg/dL) 7.6 (3.0925–12.545) 6.36 (2.52–11.08) 0.41
Serum procalcitonin concentration (ng/mL) 0.8 (0.245–2.5125) 0.405 (0.1625–6.317) 0.074
N-terminal pro-brain natriuretic peptide (pg/mL) 336 (146–811.5) 510 (130–983.5) 0.55
Soluble interleukin-2 receptor (U/mL) 1585 (1087.5–2090) 1660 (1070–2360) 0.59
Urinary β 2-microglobulin/creatinine ratio 19.36 (5.92–151.9) 21.57 (5.97–130.74) 0.98
YPT positive group 6 (15 %) 5 (7.35 %) 0.32
High risk patients; n (%) 10 (25 %) 19 (27.9 %) 0.82
High risk YPT positive; n (%) 2 (5 %) 1 (1.47 %) 0.55
High risk patients with CS; n (%) 2 (20 %) 1 (5.26 %) 0.27
High risk, YPT positive, CS; n (%) 1 (50 %) 1 (100 %) 1
Values expressed as count (%) for categorical variables and median (IQR) for continuous variables
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gene [21]. In 1997, Abe et al. reported detection of anti-
YPM antibodies in 61 % of acute phase patients with
YPT infection. Patients with systemic symptoms such as
lymphadenopathy, transient renal dysfunction, and arth-
ritis had significantly higher titers of anti-YPM than pa-
tients with gastrointestinal tract symptoms alone [14].
We speculate that checking for anti-YPM antibody
would increase the rate of detection of YPT in KD pa-
tients. Further studies are required to ascertain whether
this is true.
We found that the incidence of CS was significantly
higher in the serologically positive group (two patients,
18 %) than in the negative group (one patient, 1 %) (p =
0.027). In 1997, Konishi et al. reported a patient with
Kawasaki disease, coronary artery aneurysms, and docu-
mented YPT type 4b infection confirmed by both micro-
biological and serological findings [4]. In 2006, Tahara et
al. reported that 22/42 KD patients with YPT infection
had coronary artery lesions, this incidence being signifi-
cantly higher than in the YPT-negative group [7]. In 2014,
Kusuda et al. reported that serum KD-specific molecules
were mostly derived from biofilms and possessed molecu-
lar structures common to microbe-associated molecular
patterns from Bacillus cereus, Bacillus subtilis, YPT and
Staphylococcus aureus. They also reported that extracts
from Bacillus cereus, Bacillus subtilis, YPT and Staphylo-
coccus aureus induced proinflammatory cytokines by
human coronary artery endothelial cells [25]. This
pathogenesis can contribute to the higher incidence
of CS in cases of KD associated with YPT.
As shown in recent published studies, new medica-
tions such as infliximab, cyclosporin, and methylprednis-
olone have been developed [18, 26–29]. These have
reduced the incidence of CS in KD patients; however,
there is still a 2.8 % incidence of CS in Japan ([http://
www.jichi.ac.jp/dph/kawasakibyou/20130909/mcls22report.
pdf] (in Japanese)). Our findings suggest that YPT infec-
tion is a major risk factor for CS in KD patients even
after the adoption of these newly developed treatment
strategies.
In this study, the only clinical distinction between KD
patients with and without YPT infection was in the inci-
dence of abdominal symptoms and CS. Of note, YPT is
usually very sensitive to most antibiotics [6, 30]. Antibi-
otics for Group-A streptococcal infection reduce the in-
cidence of acute rheumatic fever [31]. In the future, we
should aim at conducting research to clarify if antibiotic
treatment for YPT infection could prevent the develop-
ment of KD or reduce the incidence of CS after rapid
diagnostic techniques for YPT are developed, such as the
loop-mediated isothermal amplification method [32].
In our cohort, treatment with IVIG + PSL, as described
in the RAISE study, did not decrease the frequency of
CS in high-risk patients. In 2012, Kobayashi et al.
reported the findings of a randomized, open-label,
blinded-endpoints trial in which 248 high-risk patients
participated (the RAISE study). They found a signifi-
cantly lower incidence of CS in patients who received
IVIG + PSL therapy than in those who received conven-
tional IVIG therapy [15]. After the publication of this
study [15], the use of steroids has been spreading for the
standard treatment of KD and the use of steroids are
recommended for the cases who did not respond to ini-
tial treatment with IVIG as written in KD treatment
guideline in Japan [18]. The recent national survey in
Japan revealed that among patients not responding to
IVIG therapy, 29.0 % of them were treated with steroids
[19]. However, it is not a routine practice in other coun-
tries because the evidence for the use of steroids is gen-
erally lacking in non-Japanese populations [33, 34].
Although RAISE protocol is widely prevalent in Japan,
further larger randomised controlled trials are required
to evaluate the use of corticosteroid therapy for both
adjunctive primary treatment in high-risk cases and
for additional ‘rescue’ therapy in IVIG non-responsive
cases [33].
In our cohort, there were fewer high-risk patients
(n = 29) and only ten of them received IVIG + PSL.
However, two of the ten high-risk patients who received
IVIG + PSL therapy had CS, indicating that even this
treatment strategy did not completely prevent CS in all
high-risk KD patients.
One limitation of our study is that no YPT was cul-
tured from patients’ blood and/or stool samples after
they had been kept in cold enrichment cultures at 27 °C.
This may be attributable to antibiotic administration be-
fore obtaining the samples, which occurred in about
60 % of our KD patients. Thus, our study lacks definitive
evidence of YPT infection in the patients with KD who
were serologically positive. Another limitation is that, al-
though this was a single-center study, our therapeutic
strategy changed during its course because of the publi-
cation of the RAISE study, which showed clear evidence
of the efficacy of steroids for KD. Further, this study in-
cluded relatively few YPT positive patients overall and
relatively few high-risk patients.
Conclusions
We documented that 10 % of our KD patients had posi-
tive anti-YPT and/or anti-YPM antibody titers and 18 %
of serologically positive patients had CS, meaning that
YPT infection is associated with a very high-risk of CS
in patients with KD. We failed to detect any other clin-
ical differences between serologically positive and nega-
tive patients, aside from gastrointestinal symptoms. We
also reported that treatment with IVIG + PSL as re-
ported by the RAISE study did not decrease the fre-
quency of CS in this study. However, our sample size
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was overly small to draw such conclusions. Further in-
vestigation in a larger cohort is necessary to confirm our
findings.
Though many studies on KD treatment have been per-
formed, few of them have focused on the cause of this
condition. Further studies are needed to clarify the effect
of YPT infection on KD and identify the cause of KD
and its optimal treatment. Furthermore, detection of
YPT infection and specific treatment in the early phase
could reduce the risk of CS.
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